Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.

Recently, 3 of Viva's portfolio companies have achieved significant results and progress. Keep reading for more details.

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), invested and incubated by Viva BioInnovator (VBI), is a clinical stage biopharmaceutical company. Recently they were pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 solution.This clinical trial in the AGA program includes 16 weeks dosing of two different active formulation strengths and placebo in a study entitled, "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia". Study objectives are to evaluate efficacy, safety and pharmacokinetics of topical TDM-105795. Approximately 12 U.S. clinical sites are currently participating in this study under an open IND with FDA.

Haiwang Alliance Interviewed Dr.Erning Xia, CTO of VivaVision, and the QY211 Gel of E-nitiate Biopharmaceuticals, A Joint Venture Subsidiary of VivaVision, Has Completed the First Dose Enrollment in Phase Ia Healthy Subjects

Recently, Haiwang Alliance interviewed Dr.Erning Xia, Chief Technology Officer of VivaVision, invested and incubated by Viva BioInnovator (VBI). He talked about his experience of joining VivaVision, and how the expert team worked together to solve the problems of formulation and R&D pipeline design. He said that for VivaVision, in the next three years, the most important thing is the approval and commercialization of new drugs, while exploring the international market. “Our goal is to deeply cultivate the ophthalmology market, develop multiple product pipelines, commercialize first in class and best in class ophthalmic drugs, and eventually become a comprehensive biopharmaceutical company and industry benchmark focusing on ophthalmology research and development, high-end ophthalmic drug production and sales"

In addition, E-nitiate Biopharmaceuticals, which was jointly established by VivaVision and Betta Fund, is currently undergoing phase I clinical study aimed to evaluate the safety and preliminary efficacy of topical QY211 gel in Chinese healthy subjects and patients with mild to moderate atopic dermatitis.

Interview with Dr.Xiangdong Qu, the Founder of QureBio, in the Special Issue of  Drug Hunter

Recently, Dr.Xiangdong Qu, the founder of QureBio, invested and incubated by Viva BioInnovator (VBI), was jointly interviewed by the Drug Hunter and Healthcare Executive. Dr.Qu introduced the basic situation of the company, drugs in development, strategic thinking, milestone events and future strategic planning. Regarding the layout of the company's drugs in development, Dr.Qu said: "We currently have two clinical stage pipelines, Q-1802 and Q-1801. Q-1802 is a CLDN18.2/PD-L1 bispecific antibody, and Q-1801 is a SIRP⍺/PD-L1 bispecific antibody; both pipelines target tumor-target cells by simultaneously activating autoimmune and adaptive immune mechanisms to attack tumors. We have a platform including phage display technology, hybridoma antibody human platform, single-domain antibody platform, and antibody engineering. As a result, QureBio has built several preclinical pipelines at different stages. In addition, in the past five years, we have also studied some potential first-in-class targets and focused on developing unique bi/multi-specific antibody technology, focusing on the next generation of solid tumor cancer treatment options."